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A bs tr ac t
Background
The level of environmental hypobaric hypoxia that affects climbers at the summit 
of Mount Everest (8848 m [29,029 ft]) is close to the limit of tolerance by humans. 
We performed direct field measurements of arterial blood gases in climbers breath-
ing ambient air on Mount Everest.
Methods
We obtained samples of arterial blood from 10 climbers during their ascent to and 
descent from the summit of Mount Everest. The partial pressures of arterial oxygen 
(PaO2) and carbon dioxide (PaCO2), pH, and hemoglobin and lactate concentrations 
were measured. The arterial oxygen saturation (SaO2), bicarbonate concentration, 
base excess, and alveolar–arterial oxygen difference were calculated.
Results
PaO2 fell with increasing altitude, whereas SaO2 was relatively stable. The hemoglobin 
concentration increased such that the oxygen content of arterial blood was main-
tained at or above sea-level values until the climbers reached an elevation of 7100 m 
(23,294 ft). In four samples taken at 8400 m (27,559 ft) — at which altitude the 
barometric pressure was 272 mm Hg (36.3 kPa) — the mean PaO2 in subjects breath-
ing ambient air was 24.6 mm Hg (3.28 kPa), with a range of 19.1 to 29.5 mm Hg 
(2.55 to 3.93 kPa). The mean PaCO2 was 13.3 mm Hg (1.77 kPa), with a range of 
10.3 to 15.7 mm Hg (1.37 to 2.09 kPa). At 8400 m, the mean arterial oxygen content 
was 26% lower than it was at 7100 m (145.8 ml per liter as compared with 197.1 ml 
per liter). The mean calculated alveolar–arterial oxygen difference was 5.4 mm Hg 
(0.72 kPa).
Conclusions
The elevated alveolar–arterial oxygen difference that is seen in subjects who are in 
conditions of extreme hypoxia may represent a degree of subclinical high-altitude 
pulmonary edema or a functional limitation in pulmonary diffusion.
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The partial pressure of atmospheric oxygen falls progressively as barometric pressure decreases with increasing altitude. 
Correspondingly, the ability to perform work 
(e.g., walking or climbing) diminishes with the 
decreased availability of atmospheric oxygen for 
aerobic respiration.1,2 At the summit of Mount 
Everest (8848 m [29,029 ft]), the highest point on 
the earth’s surface, the partial pressure of in-
spired oxygen (PiO2) is believed to be very close 
to the limit that acclimatized humans can toler-
ate while maintaining functions such as ambula-
tion and cognition.3 Hillary and Tenzing used 
supplemental oxygen to achieve the first ascent 
of Everest in 1953. It was not until 25 years after 
their ascent that the first ascent of Everest with-
out supplemental oxygen was made by Messner 
and Habeler.4 Currently, less than 4% of persons 
who climb Everest do so without the use of sup-
plemental oxygen (Salisbury R., Himalayan data-
base: personal communication).
The only published measurements of the par-
tial pressure of oxygen in arterial blood (PaO2) 
at such a low barometric pressure were reported 
in two studies — Operation Everest II and Opera-
tion Everest III (Comex ’97) — that were designed 
to simulate an ascent of Mount Everest by plac-
ing subjects in a hypobaric chamber.5,6 The sub-
jects in the two studies had a mean (±SD) resting 
PaO2 of 30.3±2.1 mm Hg (4.04±0.28 kPa)5 and 
30.6±1.4 mm Hg (4.08±0.19 kPa),6 respectively, 
at a barometric pressure equivalent to the summit 
of Mount Everest (253.0 mm Hg, or 33.73 kPa). 
Such profound hypoxemia was tolerable because 
the subjects had been gradually acclimatized to 
the simulated altitude over a period of 37 to 40 
days. In 1981, the partial pressures of oxygen 
and carbon dioxide (PaCO2) at end expiration were 
measured in a single person on Everest’s summit 
after the person had been breathing without 
supplemental oxygen for approximately 10 min-
utes.7 With the use of a classic Bohr integration, 
the PaO2 for this climber was estimated to be 
28 mm Hg (3.73 kPa).
We made direct field measurements of PaO2 
and arterial oxygen content (CaO2) in climbers 
breathing ambient air at these extreme altitudes.
Me thods
Study Participants
We obtained approval for this study from the 
University College London Committee on the Eth-
ics of Non-NHS Human Research. All participants 
gave written informed consent. The subjects in 
this study were 10 healthy climbers (9 men and 
1 woman, ranging in age from 22 to 48 years), 
who were ascending Everest by its southeast ridge 
as part of a medical research expedition (Caudwell 
Xtreme Everest).8,9
All subjects had ascended higher than 6800 m 
(22,310 ft) without incident on previous expedi-
tions, and all were well acclimatized, with no evi-
dence of ill effects from high altitude or of other 
illnesses. Subjects who were ascending higher 
than 7950 m (26,083 ft) had all previously ascend-
ed higher than that altitude without incident.
Collection of Blood Samples
Arterial blood samples were obtained in London, 
at an altitude of 75 m (246 ft); at the Everest base 
camp, at an altitude of 5300 m (17,388 ft); in 
Camp 2, at an altitude of 6400 m (20,997 ft); 
in Camp 3, at an altitude of 7100 m (23,294 ft); 
and during the descent from the summit at a fea-
ture known as the Balcony, at an altitude of 8400 m 
(27,559 ft) (Fig. 1). The samples that were obtained 
in London and at the Everest base camp were 
obtained with the subject at rest, with the use 
of indwelling radial arterial cannulae that were 
placed as part of other study protocols; these 
samples were analyzed immediately. Samples ob-
tained at an altitude higher than the Everest base 
camp were obtained from the right femoral artery, 
identified by digital palpation. Intraarterial place-
ment of the needle (21-gauge) was confirmed by 
pulsatile filling of a heparinized 2-ml oiled glass 
syringe (Fisher Scientific). Syringes were imme-
diately sealed with an airtight cap and placed in 
a plastic bag, which in turn was placed in an ice-
water slurry inside an insulated vacuum flask. 
The flask was rapidly transported to a laboratory 
at Camp 2 in the Western Cwm; the length of time 
for this transfer to be completed was recorded. 
Barometric pressure was measured at the altitude 
at which the blood samples were taken, with the 
use of a handheld digital barometer (GPB 2300, 
Greisinger Electronic). Arterial samples were ob-
tained by two investigators, both of whom had 
extensive experience with cannulation of the fem-
oral artery and blood sampling.
Supplemental Oxygen
Supplemental oxygen was used only at or above 
Camp 3 (7100 m), with the following flow rates: 
2 to 3 liters per minute while the subject was 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;2 nejm.org january 8, 2009142
climbing and 0.5 liter per minute while the sub-
ject was sleeping. Supplemental oxygen was infre-
quently used while the subjects were resting at 
Camp 3 and Camp 4 (7950 m). At Camp 3, arte-
rial samples were obtained after the subjects had 
been breathing ambient air for at least 4 hours. 
At the Balcony, samples were obtained after the 
subjects had been breathing ambient air for 20 
minutes in order to achieve an adequate washout 
of supplemental oxygen.
Analysis of Blood Samples
Arterial blood samples were analyzed with the 
use of the RapidLab 348 (Siemens Medical Solu-
tions Diagnostics) blood gas analyzer, which does 
not contain a co-oximeter. The PaO2, the PaCO2, 
and the pH were measured. Values for the bicar-
bonate concentration, blood base excess, and oxy-
gen saturation (SaO2) were calculated with the 
use of formulas currently approved by the Clini-
cal Laboratory Standards Institute10 (Table 1). The 
blood lactate concentration was measured with a 
separate device (Lactate Scout, EKF Diagnostic). 
Barometric pressure was measured at the site of 
analysis with the use of the same model of barom-
eter as that used at the sampling site.
The blood gas analyzer was altered from its 
original specification so that it would function at 
high altitude. The analyzer’s internal barometer 
was bypassed with a fixed resistor so that the 
analyzer always read as if the barometric pressure 
was a constant 450 mm Hg (60.0 kPa), regard-
less of altitude. This modification was necessary 
in order to circumvent an inbuilt mechanism that 
prevented the analysis of samples at a baromet-
ric pressure lower than 400 mm Hg (53.3 kPa). 
To replicate the barometric-pressure correction 
that the machine would normally apply in its un-
modified form, true gas partial-pressure values 
were obtained by inserting the machine-derived 
values into Equation 1, shown in Table 1. This 
calculation is identical to that performed inter-
nally by the arterial blood gas analyzer during 
normal function at lower altitudes.
The subjects’ temperatures at the time of sam-
pling were assumed to be the same as the tem-
perature of the blood gas analyzer — namely, 
37.0°C (98.6°F). The analyzer was validated in a 
hypobaric chamber at the equivalent of 4000 m 
(13,123 ft) and then revalidated in the field, at 
5300 m and 6400 m, the altitudes at which mea-
surements of arterial blood gas were performed 
Figure 1. Barometric Pressure (Pb) and Partial Pressure of Inspired Oxygen 
(PiO2) in Blood Samples Obtained from Subjects Breathing Ambient Air  
at Various Altitudes between London and the Summit of Mount Everest.
In Panel A, the measurements at the summit are reported from West et al.7 
The other measurements were performed by the investigators.
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in this study. Validation involved the analysis of 
aqueous trilevel quality-control solutions (RapidQC 
Plus, Bayer HealthCare) with known values of pH, 
PaO2, and PaCO2. Two-point calibration of the 
RapidLab 348 gas sensors and electrodes was 
performed automatically according to the manu-
facturer’s specifications with the use of standard 
gases and electrolyte solutions, respectively. Each 
arterial blood sample was analyzed three times, 
and the mean of these values is reported. Because 
the pulse oximeters available to us were not cali-
brated below 70% SaO2, we chose to calculate 
SaO2 using Equation 2, shown in Table 1. All 
reported values for SaO2 are calculated values, 
except for the values for four subjects at an alti-
tude of 5300 m; for these subjects, values ob-
tained by peripheral-pulse oximetry (Onyx 9500, 
Nonin) are reported owing to an isolated failure 
of the pH electrode on the blood gas machine, 
an electrode that was subsequently replaced. All 
measured and calculated values for SaO2 at an 
altitude of 5300 m fell within the calibrated range 
of the pulse oximeter.
The hemoglobin concentration was measured 
in venous blood collected from subjects in London 
before the expedition, at the Everest base camp 
(at 2-week intervals during the expedition), and 
at Camp 2, with the use of a handheld photo-
Table 1. Equations Used for the Calculation of Arterial Blood Gas Values and Arterial Oxygen Content.*
1. Actual partial pressure of oxygen in arterial blood samples (PaO2)
            measured Pb at site of ABG machine – SVP
resistor set Pb (i.e., 450 mm Hg) – SVP
2. Arterial oxygen saturation (SaO2)†
                             N4 – (15 × N3) + (2045 × N2) + (2000 × N)
N4 – (15 × N3) + (2400 × N2) – (31,100 × N) + (2.4 × 106)
N = PO2 × 10[0.48 × (pH – 7.4) – 0.0013 × BE]
3. Bicarbonate concentration (HCO3−)† 
HCO3− (mmol/liter) = 0.0307 × PaCO2 × 10(pH – 6.105)
4. Blood base excess (BE)†
BE = (1 − 0.014 × Hb) × (HCO3−  − 24.8) + (7.7 + 1.43 × Hb) × (pH −7.4)
5. Partial pressure of inspired oxygen (PiO2)
PiO2 = (Pb – SVP) × FiO2 
6. Partial pressure of alveolar oxygen (PaO2) — The “alveolar gas equation”
                        PaCO2 + [ PaCO2 × FiO2 × 1 – RER ]RER                                     RER
PaCO2 was assumed to be equal to PaCO2
7. Arterial oxygen content (CaO2)
CaO2 = SaO2 × Hb × 1.39 + (PaO2 × 0.03)
* ABG denotes arterial blood gas, BE base excess, FiO
2
 fraction of inspired oxygen, Hb hemoglobin concentration, PaCO2 
partial pressure of alveolar carbon dioxide, PaCO2 partial pressure of arterial carbon dioxide, Pb barometric pressure, 
PO2 partial pressure of oxygen, RER respiratory exchange ratio, and SVP saturated vapor pressure at body temperature 
(47 mm Hg).
† This equation is currently approved by the Clinical Laboratory Standards Institute (http://www.clsi.org).10
× value of PO2 given by ABG machine
× 100
PaO2 = 
SaO2(%) = 
PaO2 = PiO2–
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metric device (HemoCue Whole Blood Hemoglo-
bin System, HemoCue). Venous samples were 
obtained at the same time as arterial samples in 
London, at the Everest base camp, and at Camp 2. 
For the hemoglobin concentration at Camp 3 and 
the Balcony, we used the mean of the hemoglo-
bin values obtained at the Everest base camp 
9 days before and 8 days after the arterial sample 
at the Balcony was obtained (Fig. 1); these values 
were used in the calculation of CaO2, bicarbonate 
concentration, and blood base excess.
The partial pressure of alveolar oxygen (PaO2) 
at the time of sampling was estimated by apply-
ing the alveolar gas equation to the calculated 
PiO2 (Equations 5 and 6 in Table 1). The resting 
respiratory exchange ratios necessary for these 
calculations were obtained for three of the sub-
jects at the South Col of Everest on the day be-
fore summiting, with the use of breath-by-
breath analysis equipment (MetaMax 3B, Cortex 
Biophysik).
R esult s
Collection of Samples
The climbers reached the summit of Mount Ever-
est on the morning of May 23, 2007, after having 
spent 60 days at an elevation higher than 2500 m 
(8202 ft). The location, altitude, barometric pres-
sure, and PiO2 for each sampling site are shown 
in Figure 1. All femoral arterial blood samples 
were obtained without complications on the first 
attempt. Ten samples were obtained in London, 
nine at the Everest base camp, nine at Camp 2, 
six at Camp 3, and four at 8400 m. The reasons 
for not obtaining samples were as follows: at the 
Everest base camp, one subject was unwell; at 
Camp 2, one subject was unwell; at Camp 3, four 
subjects were not present when the Sherpa was 
available to transport the sample; and at the Bal-
cony, two subjects did not reach this altitude, and 
four subjects were not present when the Sherpa 
was available to transport the sample. One sam-
ple at Camp 2 repeatedly clotted in the arterial 
blood gas machine, so no data are available for 
that sample. In all cases, the interval between sam-
pling and analysis was less than 2 hours.
Arterial Blood Gases
Measured PaO2 and hemoglobin values, along 
with calculated SaO2 and CaO2 values, are shown 
in Figure 2. The CaO2 value at sea level was main-
tained up to an altitude of 7100 m and fell below 
baseline only at 8400 m; at this altitude, the mean 
CaO2 for the four subjects was calculated to be 
145.8 ml per liter. Mean PaCO2 values fell with 
increasing altitude, from 36.6 mm Hg (4.88 kPa) 
at sea level to 20.4 mm Hg (2.72 kPa) at 5300 m, 
18.2 mm Hg (2.43 kPa) at 6400 m, and 16.7 mm Hg 
(2.23 kPa) at 7100 m; corresponding pH values 
were 7.40, 7.46, 7.51, and 7.53.
The results of the arterial blood gas analysis 
and the hemoglobin and lactate concentrations in 
four subjects at 8400 m are shown in Table 2. The 
mean PaO2 and PaCO2 values were 24.6 mm Hg 
(3.28 kPa) and 13.3 mm Hg (1.77 kPa), respec-
tively. The mean PiO2 value at 8400 m was calcu-
lated to be 47.0 mm Hg (6.27 kPa) at the time of 
arterial sampling. Calculated values for PaO2, 
resting respiratory exchange ratios, and the alveo-
lar–arterial oxygen difference in four subjects at 
8400 m are shown in Table 2. The mean PaO2 and 
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the mean alveolar–arterial oxygen difference were 
30.0 mm Hg (4.00 kPa) and 5.4 mm Hg (0.72 kPa), 
respectively. None of the subjects were consid-
ered, on clinical grounds, to have high-altitude 
pulmonary edema during the study period.
Discussion
These measurements of arterial blood gases and 
hemoglobin levels in climbers on Mount Everest 
provide a picture of the pattern and limits of 
changes in human blood gases in response to 
hypobaric hypoxia on the earth’s highest moun-
tain. Because of adverse weather conditions, we 
were unable to obtain arterial samples at the 
summit of Mount Everest as originally planned. 
Consequently, the samples at the highest altitude 
were obtained during the descent from the sum-
mit. A small shelter was erected at the first safe 
location, an area known as the Balcony, which is 
located at an altitude of 8400 m, and the blood 
sampling took place in this shelter. The values 
for PaO2 and SaO2 reported here are, to our knowl-
edge, among the lowest ever documented in hu-
mans. The results of a study of alveolar breath 
samples obtained from divers suggest that breath-
hold divers may have PaO2 levels that are lower 
than 30 mm Hg (4.0 kPa), but no direct measure-
ments have been reported.11 Similar values have 
been reported in a study of samples obtained at 
a high altitude, but in that study, measurements 
were obtained from subjects who had high-alti-
tude pulmonary edema.12,13
Decreases in PaO2 are broadly proportional to 
the fall in barometric pressure with increasing 
altitude, whereas SaO2 is relatively well maintained 
(in relation to barometric-pressure changes) owing 
to the characteristics of the oxygen–hemoglobin 
dissociation curve and the effects of respiratory 
acclimatization (decreased PaCO2). Increases in 
the hemoglobin concentration compensate for the 
fall in SaO2 such that CaO2 is maintained until 
Table 2. Arterial Blood Gas Measurements and Calculated Values for Pulmonary Gas Exchange from Four Subjects  
at an Altitude of 8400 m, during Descent from the Summit of Mount Everest.*
Variable Subject No. Group Mean
1 2 3 4
pH 7.55 7.45 7.52 7.60 7.53
PaO2 (mm Hg)† 29.5 19.1 21.0 28.7 24.6
PaCO2 (mm Hg)† 12.3 15.7 15.0 10.3 13.3
Bicarbonate (mmol/liter)‡ 10.5 10.67 11.97 9.87 10.8
Base excess of blood‡ −6.3 −9.16 −6.39 −5.71 −6.9
Lactate concentration (mmol/liter) 2.0 2.0 2.9 1.8 2.2
SaO2 (%)‡ 68.1 34.4 43.7 69.7 54.0
Hemoglobin (g/dl)§ 20.2 18.7 18.8 19.4 19.3
Respiratory exchange ratio¶ 0.81 0.74‖ 0.72 0.70 0.74
PaO2 — mm Hg†** 32.4 26.9 27.4 33.2 30.0
Alveolar–arterial oxygen difference — mm Hg† 2.89 7.81 6.44 4.51 5.41
* PaCO2 denotes partial pressure of arterial carbon dioxide, PaO2 partial pressure of alveolar oxygen, PaO2 partial pres­
sure of arterial oxygen, and SaO2 calculated arterial oxygen saturation.
† To convert the values for PaO2, PaCO2, PaO2, and the alveolar–arterial oxygen difference to kilopascals, multiply by 
0.1333.
‡ These values were calculated with the use of the algorithms currently approved by the Clinical Laboratory Standards 
Institute.10
§ The values for hemoglobin are the mean values of measurements obtained at 5300 m (17,388 ft) 9 days before and 8 
days after the arterial blood sampling.
¶ The respiratory exchange ratio was measured at an elevation of 7950 m while the subject was resting.
‖ No measured respiratory exchange ratio was available for this subject; the value was derived from the mean values 
for the other three subjects.
** PaO2 was calculated with the use of the full alveolar gas equation.
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a person reaches an altitude of at least 7100 m. 
Thus, changes in CaO2 do not provide an explana-
tion for the significant limitations in individual 
performance previously reported at these altitudes 
(a reduction in maximum oxygen consumption 
of 30 to 35% at 5300 m1,7). CaO2 at 8400 m is 
significantly lower than that at sea level, and the 
marked interindividual variability at this altitude 
is related predominantly to differences in SaO2, 
probably reflecting a combination of variation in 
ventilatory acclimatization, hypoxic ventilatory 
response, hypoxic ventilatory depression, and the 
alveolar–arterial oxygen difference, as discussed 
below.
At the highest altitude at which samples were 
obtained, the subjects had an impressive adaptive 
response (i.e., acclimatization) to prolonged and 
extreme environmental hypoxia. Persons who are 
not acclimatized lose consciousness within 2 to 3 
minutes when they are exposed suddenly to lev-
els of ambient hypoxia equivalent to those at alti-
tudes higher than 8534 m (27,999 ft).14 In con-
trast, our subjects had apparently clear cognition, 
as evidenced by effective radio communication 
and, in the case of two of the subjects, the per-
formance of complication-free sampling of arte-
rial blood gases. The absence of obvious neuro-
cognitive abnormalities suggests that cerebral 
hypoxia was not manifested as a substantial dys-
function at the time of blood sampling. This is 
of interest in view of the evidence that there is a 
risk of long-term cognitive deficit and structural 
neurologic damage from exposure to these ex-
treme altitudes.15-17 Despite chronic hypoxemia, 
none of the subjects in this study had clinically 
significant hyperlactatemia (mean lactate concen-
tration, 2.2 mmol per liter at the highest altitude), 
consistent with findings in resting subjects ex-
posed to hypobaric hypoxia.5 This suggests that 
anaerobic metabolism does not contribute sub-
stantially to energy production at an extreme alti-
tude while a person is at rest. An alternative, or 
additional, explanation is the possibility of in-
creased lactate use as a fuel source at extreme 
altitudes.18
We cannot exclude the possibility that the use 
of supplemental oxygen at and above Camp 3 was 
a confounding influence on the acclimatization 
process and thus on PaO2 and PaCO2. Supple-
mental oxygen benefits climbers subjectively and 
improves SaO2 in the resting state and during 
exercise.19 During this study, the safety benefits 
related to supplemental oxygen were considered 
to be of overriding importance while the subjects 
were climbing on Mount Everest.20 We believe that 
the 20-minute rest period that the subjects had 
without supplemental oxygen before arterial sam-
pling should have been more than adequate to 
ensure a washout of supplemental oxygen from 
the circulation. However, the effects on ventila-
tion of suddenly removing supplemental oxygen 
at such an altitude are unknown. Climbers who 
reach the summit of Mount Everest without us-
ing supplemental oxygen may have more effective 
ventilatory acclimatization than those who use 
supplemental oxygen, and they may therefore 
have a higher PaO2 while breathing ambient air 
than do those who choose to use supplemental 
oxygen. Removing supplemental oxygen in a hy-
poxic environment is known to trigger two se-
quential yet variable phenomena. The hypoxic 
ventilatory response leads to hyperventilation 
within minutes after exposure to hypoxia and is 
followed by hypoxic ventilatory depression ap-
proximately 10 to 30 minutes after exposure.21 
The effect of these opposing responses to hypoxia 
on the PaO2 and PaCO2 values in this study is 
difficult to quantify. Interindividual variability in 
the hypoxic ventilatory response and hypoxic ven-
tilatory depression may account for the variabil-
ity in arterial blood gas values in our subjects as 
compared with the results of a study involving 
subjects in a hypobaric chamber, in which supple-
mental oxygen was not used immediately before 
sampling.5
The methods of storage and transportation of 
the blood samples in this study were used by our 
group on two previous expeditions to extreme al-
titudes and were shown to be effective. The time 
lapse between sampling and analysis was 2 hours 
or less in all cases. The effect of storing blood 
in this manner has been described previously22; 
the partial pressure of oxygen in the blood sam-
ples rose approximately 0.75 mm Hg (0.1 kPa) 
after 2 hours of storage. Our own experiments 
at sea level have shown a similar mean rise in the 
partial pressure of oxygen (1.1 mm Hg [0.15 kPa]) 
in samples of venous blood after 2 hours. There-
fore, any effect of the duration of storage and 
transportation on the reported values would 
tend to lead to a small overestimation of mea-
sured PaO2.
Our findings are consistent with the results 
of the previous three studies of PaO2 in extreme 
arterial blood gases and oxygen content in climbers on mount everest
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hypobaric conditions.5-7 The mean measured PaO2 
in our study was 24.6 mm Hg (3.28 kPa) at 
8400 m, as compared with 30.3 mm Hg (4.04 kPa)5 
or 30.6 mm Hg (4.08 KPa)6 at a simulated alti-
tude of 8848 m, and 28.0 mm Hg (3.73 kPa) as 
estimated by West et al. from an alveolar gas 
sample obtained at 8848 m.7 The mean PaO2 in 
our subjects was lower than these values, despite 
the fact that our subjects were at a slightly higher 
barometric pressure (lower altitude). The PaCO2 
reported in the study by West et al.7 was only 
7.5 mm Hg (1.0 kPa), slightly more than half the 
mean PaCO2 reported in this study (13.3 mm Hg 
[1.78 kPa]). This finding may be explained by the 
fact that the subject from whom the alveolar gas 
sample was collected in the study of West et al.7 
was known to have an extremely brisk hypoxic 
ventilatory response.23 Possible explanations for 
the differences between the data in this study and 
the results of previous hypobaric-chamber studies 
may be related to differences in ascent profiles, 
activity levels, and the use of supplemental oxy-
gen. In the hypobaric-chamber studies, the sub-
jects were exposed to hypobaric conditions for 
a period of 37 to 40 days,5,6 as compared with 
60 days in this study (Fig. 1), and although they 
underwent periodic exercise tests, activity levels 
were much lower than those in our subjects, who 
were climbing to the summit of Everest. Where-
as subjects in our study used supplemental oxy-
gen as described, subjects in Operation Everest II 
were similarly exposed to an elevated fraction of 
inspired oxygen either because the chamber pres-
sure was increased at night to help them sleep or 
during the conduct of pulmonary artery catheter-
ization studies.5,24
At an altitude of 8400 m, the mean calculated 
PaO2 was 30.0 mm Hg (4.00 kPa), and the mean 
calculated alveolar–arterial oxygen difference was 
5.4 mm Hg (0.72 kPa) (Table 2). It is known that 
the alveolar–arterial oxygen difference decreases 
as the PiO2 falls.25 Both theoretical considerations 
and empirical data suggest that the alveolar–
arterial oxygen difference should be less than 
2 mm Hg (0.27 kPa) under these conditions26; 
Sutton et al. report a mean alveolar–arterial oxy-
gen difference of 1.5 mm Hg (0.20 kPa) in rest-
ing healthy persons at the simulated altitude of 
8848 m.5
Hypoxia associated with an increased alveolar–
arterial oxygen difference may be attributable to 
shunting, a ventilation–perfusion mismatch, or a 
limitation in pulmonary diffusion. We speculate 
that the relatively high alveolar–arterial oxygen 
difference in the subjects in this study may be 
the result of subclinical high-altitude pulmonary 
edema contributing to both a ventilation–perfu-
sion mismatch and impairment of pulmonary 
diffusion. An alternative explanation might be 
disequilibrium in pulmonary alveolar–end-capil-
lary diffusion, which has been shown to occur in 
conditions of hypobaric hypoxia.27,28 Previous in-
vestigators have observed an increased alveolar–
arterial oxygen gradient after strenuous exercise 
in subjects exposed to hypobaric hypoxia,25,29,30 
and this may be a key difference between the re-
sults of this study and those of previous investiga-
tions involving subjects in a hypobaric chamber.
In our study, arterial blood sampling was per-
formed with subjects in the supine position, and 
this factor may have confounded measurements 
through mechanisms such as increased basal 
atelectasis or central fluid shifts that can be detri-
mental to pulmonary gas exchange. PaO2 has been 
reported to be inversely related to the alveolar–
arterial oxygen difference30; this finding may 
explain the low PaO2 in Subject 2 (19.1 mm Hg 
[2.55 kPa]), the subject in the group who had the 
highest alveolar–arterial oxygen difference. The 
respiratory exchange ratios in subjects who had 
just reached the summit of Mount Everest may 
be higher than those that were measured at a 
resting steady state the previous day on the South 
Col at 7950 m. However, such an elevation in 
respiratory exchange ratios would only serve to 
increase the alveolar–arterial oxygen difference 
and increase the significance of these findings. 
For example, if the respiratory exchange ratio 
was assumed to be 1.0 in all four subjects at the 
time of blood sampling, the mean alveolar–arterial 
oxygen difference would be 9.1 mm Hg (1.21 kPa), 
instead of 5.4 mm Hg (0.72 kPa).
Tissue hypoxia is a universal phenomenon 
among persons who are critically ill31 and is of-
ten the result of arterial hypoxemia. In conjunc-
tion with the initiating factor and the presence of 
any coexisting condition, hypoxia triggers numer-
ous adaptive and maladaptive systemic responses 
that remain poorly understood. Defining the 
limits of hypoxia tolerance is of direct relevance 
to physicians who care for critically ill patients 
because many interventions that are aimed at re-
storing or maintaining cellular oxygenation have 
proven ineffective or even detrimental. For ex-
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ample, a high PiO2 can have pulmonary toxic 
effects.32 Moreover among patients with estab-
lished critical illness, increasing the hemoglobin 
concentration to increase oxygen carriage may not 
provide a clinical benefit,33 and a goal-directed 
elevation of systemic oxygen can be detrimental.34 
Useful insights may be gained by examining 
the biophysiologic responses of healthy persons 
who are exposed to low levels of environmental 
oxygen.
In summary, we report field measurements of 
the partial pressure of oxygen and carbon dioxide, 
pH, and hemoglobin and lactate concentrations in 
the arterial blood of humans at extreme altitudes. 
We speculate that the calculated alveolar–arterial 
oxygen difference in these subjects suggests a 
degree of functional limitation in pulmonary dif-
fusion or subclinical pulmonary edema, condi-
tions that may explain why the values for PaO2 
are lower than expected.
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